Drug developer Cennerv lodges prospectus for Catalist IPO

Singapore

SINGAPORE-based biotech Cennerv Pharmaceuticals, a developer of drugs to treat central nervous system (CNS) disorders, lodged a preliminary prospectus on Wednesday for a planned initial public offering (IPO) on the Singapore Exchange's Catalist board.

Details of the pricing, amount to be raised and timing of the offering have not yet been announced. PrimePartners Corporate Finance is the sponsor, issue manager and placement agent for the IPO.